Please assess the completion status of the following clinical trial:

Trial Title: Cord Blood Infusion for Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~An individual is eligible for inclusion if all of the following apply:~1. Is 18-80 years old~2. Has had a recent (within the past 9 days), acute, cortical, hemispheric, ischemic stroke in the middle cerebral artery (MCA) distribution without a midline shift as detected by magnetic resonance imaging (MRI) as a diffusion-weighted image (DWI) abnormality~3. Has a National Institutes of Health Stroke Scale (NIHSS) score of 8-15 (R) and 8-18 (L) at the time of enrollment with no more than a 4 point increase (worsening of score) from the baseline score compared to 24 hours prior to infusion~4. Subjects must have a platelet count \>100,000/uL, hemoglobin \>8gm/dl, and white blood cell count (wbc) \>2,500/uL.~5. Subjects who received tissue plasminogen activator (tPA) or underwent mechanical reperfusion may be included in the study.~6. Is able to provide consent to study or consent is obtained from the subject's legally authorized representative~7. Subjects of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after intervention so that, in the opinion of the investigator, they will not become pregnant during the course of the study~8. Is a good candidate for the trial, in the opinion of the investigator~9. Agrees to participate in follow up visits~10. Has an ABO/Rh matched umbilical cord blood unit with a minimum of 0.5 x 10\^7 total nucleated cells (TNCC)/kg based on the pre-cryopreservation TNCC.~Exclusion Criteria:~An individual is ineligible to participate if any of the following apply.~Medical Conditions:~1. Has a medical history of neurological or orthopedic pathology with a deficit as a consequence that results in a modified Rankin Scale \>1 before stroke or has a pre-existing cognitive deficit~2. Has clinically significant and/or symptomatic hemorrhage associated with stroke~3. Has new intracranial hemorrhage, edema, or mass effect that may place patient at increased risk for secondary deterioration when assessed prior to infusion~4. Has hypotension as defined as the need for IV pressor support of systolic blood pressure \<90~5. Has isolated brain stem stroke~6. Has pure lacunar stroke~7. Requires mechanical ventilation~8. Requires a craniotomy~9. Has a serious psychiatric or neurological disease which could alter evaluation on functional or cognitive scales~10. Has an active systemic infection or is HIV positive~11. Has had an active malignancy within 3 years prior to the start of screening excluding skin cancers other than melanoma~12. Has known coagulopathy such as Factor V Leyden, AntiPhospholipid Syndrome (APC), Protein C, Protein S deficiency, sickle cell, anticardiolipin antibody, or phospholipid syndrome~13. Has any concurrent illness or condition that in the opinion of the investigator might interfere with treatment or evaluation of safety~14. Has current or recent history of alcohol or drug abuse, or stroke associated with drug abuse~15. Pregnant as documented by urine or blood test~Concomitant or Prior Therapies:~1. Subjects currently receiving immunosuppressant drugs~2. History of prior transfusion reaction~3. Currently on dialysis~4. Recipient of bone marrow or organ transplant~5. Renal insufficiency with serum creatinine \>2.0 mg/dL~6. Hepatic insufficiency (bilirubin \>2.5mg/dL or transaminases \>5x the upper limit of normal). Patients with Gilberts syndrome are eligible for study enrollment if other liver function tests are normal, regardless of bilirubin level.~7. Any previous or current treatment with angiogenic growth factors, cytokines, gene or stem cell therapy~8. Subjects participating in another interventional clinical trial of an investigational therapy within 30 days of screening~Other:~1. Pregnant or lactating women~2. Unable to be evaluated for follow up visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Allogeneic Umbilical Cord Blood Infusion (Type: EXPERIMENTAL): All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete